1. Home
  2. AYTU vs LDWY Comparison

AYTU vs LDWY Comparison

Compare AYTU & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • LDWY
  • Stock Information
  • Founded
  • AYTU N/A
  • LDWY 1990
  • Country
  • AYTU United States
  • LDWY United States
  • Employees
  • AYTU N/A
  • LDWY N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • LDWY Advertising
  • Sector
  • AYTU Health Care
  • LDWY Consumer Discretionary
  • Exchange
  • AYTU Nasdaq
  • LDWY Nasdaq
  • Market Cap
  • AYTU 8.3M
  • LDWY 6.9M
  • IPO Year
  • AYTU N/A
  • LDWY 1991
  • Fundamental
  • Price
  • AYTU $2.59
  • LDWY $4.27
  • Analyst Decision
  • AYTU
  • LDWY
  • Analyst Count
  • AYTU 0
  • LDWY 0
  • Target Price
  • AYTU N/A
  • LDWY N/A
  • AVG Volume (30 Days)
  • AYTU 3.4M
  • LDWY 6.2K
  • Earning Date
  • AYTU 05-14-2025
  • LDWY 05-13-2025
  • Dividend Yield
  • AYTU N/A
  • LDWY N/A
  • EPS Growth
  • AYTU N/A
  • LDWY N/A
  • EPS
  • AYTU N/A
  • LDWY N/A
  • Revenue
  • AYTU $77,232,000.00
  • LDWY $42,183,000.00
  • Revenue This Year
  • AYTU N/A
  • LDWY N/A
  • Revenue Next Year
  • AYTU $8.14
  • LDWY N/A
  • P/E Ratio
  • AYTU N/A
  • LDWY N/A
  • Revenue Growth
  • AYTU N/A
  • LDWY 425.12
  • 52 Week Low
  • AYTU $0.95
  • LDWY $3.02
  • 52 Week High
  • AYTU $3.45
  • LDWY $5.88
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 82.21
  • LDWY 62.01
  • Support Level
  • AYTU $1.20
  • LDWY $3.83
  • Resistance Level
  • AYTU $1.31
  • LDWY $4.00
  • Average True Range (ATR)
  • AYTU 0.13
  • LDWY 0.19
  • MACD
  • AYTU 0.05
  • LDWY 0.03
  • Stochastic Oscillator
  • AYTU 74.52
  • LDWY 66.62

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About LDWY Lendway Inc. (DE)

Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.

Share on Social Networks: